Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities

Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities

Artificial intelligence tools promise transformative impacts in drug development. Regulatory agencies face challenges in integrating AI while ensuring reliability and safety in clinical trial approvals, drug marketing authorizations, and post-market surveillance. Incorporating these technologies int...

Full description

Bibliographic Details
Main Authors: Wahiba Oualikene-Gonin, Marie-Christine Jaulent, Jean-Pierre Thierry, Sofia Oliveira-Martins, Laetitia Belgodère, Patrick Maison, Joël Ankri, The Scientific Advisory Board of ANSM
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Pharmacology
Subjects:
artificial intelligence
health policy
regulatory science
drug lifecycle
drug approval process
patient safety
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1437167/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1437167/full

Similar Items